Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Shigellosis is a bacterial infection leading to dysentery and is caused by Shigella, which are small, ubiquitous Gram-negative bacteria belonging to the enterobacteria family. There are four species: S. dysenteriae, S. flexneri, S. boydii and S. sonnei, all of which cause bacillary dysentery and are strictly limited to human hosts.
Biomarker and diagnostic research for shigellosis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
10 clinical trials registered, 5 recruiting. Interventions under study include biologic therapy, other interventions, and drug therapy. Pipeline includes 1 PHASE3, 4 PHASE2, 4 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05961059](https://clinicaltrials.gov/study/NCT05961059) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 9:38 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia |
PHASE1 |
Leiden University Medical Center |
RECRUITING |
[NCT05959616](https://clinicaltrials.gov/study/NCT05959616) | Shigella Sonnei 53G Human Infection Study in Kenyan Adults | PHASE1 | University of Oxford | RECRUITING |
[NCT07433426](https://clinicaltrials.gov/study/NCT07433426) | The Impact of Shigellosis and Recommended Treatment in Children | PHASE2 | Johns Hopkins Bloomberg School of Public Health | RECRUITING |
[NCT07049159](https://clinicaltrials.gov/study/NCT07049159) | Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old | PHASE2 | Eveliqure Biotechnologies GmbH | RECRUITING |
[NCT07205926](https://clinicaltrials.gov/study/NCT07205926) | First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults | PHASE1 | Inventprise Inc. | RECRUITING |
216 publications have been identified in PubMed for shigellosis. Research spans Epidemiology / Natural History (31%), Basic Science / Preclinical (30%), and Gene Therapy / Novel Therapeutics (9%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 59 | 31% |
Laboratory research | 58 | 30% |
New treatment approaches | 18 | 9% |
Research summaries | 16 | 8% |
Clinical study results | 15 | 8% |
Patient case studies | 14 | 7% |
Testing and diagnosis research | 10 | 5% |
Other research | 2 | 1% |
Vasant B (2026). [PMID: 41871323](https://pubmed.ncbi.nlm.nih.gov/41871323/). *Commun Dis Intell (2018)*. [Clinical Trial Publication]
Alamri SA (2026). [PMID: 41817909](https://pubmed.ncbi.nlm.nih.gov/41817909/). *J Epidemiol Glob Health*. [Epidemiology / Natural History]
Chatterjee J (2026). [PMID: 41701335](https://pubmed.ncbi.nlm.nih.gov/41701335/). *J Mol Evol*. [Case Report / Case Series]
Scarlata GGM (2026). [PMID: 41892478](https://pubmed.ncbi.nlm.nih.gov/41892478/). *Antibiotics (Basel, Switzerland)*. [Review / Meta-Analysis]
Lytle E (2026). [PMID: 41769544](https://pubmed.ncbi.nlm.nih.gov/41769544/). *Cureus*. [Case Report / Case Series]
Aslanian-Kalkhoran L (2026). [PMID: 41804751](https://pubmed.ncbi.nlm.nih.gov/41804751/). *Iran J Immunol*. [Basic Science / Preclinical]
Zhang CX (2026). [PMID: 41454572](https://pubmed.ncbi.nlm.nih.gov/41454572/). *Clin Transl Sci*. [Clinical Trial Publication]
Di Benedetto R (2026). [PMID: 42099609](https://pubmed.ncbi.nlm.nih.gov/42099609/). *Front Immunol*. [Clinical Trial Publication]
Sadredinamin M (2026). [PMID: 41691281](https://pubmed.ncbi.nlm.nih.gov/41691281/). *Gut Pathog*. [Case Report / Case Series]
Schultes OL (2026). [PMID: 41379743](https://pubmed.ncbi.nlm.nih.gov/41379743/). *J Infect Dis*. [Epidemiology / Natural History]
AI-curated news mentioning shigellosis
Updated Apr 2, 2015
Cipro-resistant Shigella is spreading in the U.S., raising concerns about multidrug-resistant shigellosis. The CDC emphasizes the importance of lab tests for effective treatment and recommends thorough handwashing to prevent infection.